0000078003false00000780032026-04-232026-04-230000078003us-gaap:CommonStockMember2026-04-232026-04-230000078003pfe:NotesDue20271.000Member2026-04-232026-04-230000078003pfe:NoteDue20292.875Member2026-04-232026-04-230000078003pfe:NoteDue20323.250Member2026-04-232026-04-230000078003pfe:NoteDue20373.875Member2026-04-232026-04-230000078003pfe:NoteDue20454.250Member2026-04-232026-04-23


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 23, 2026

PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170
(State or other(Commission File(I.R.S. Employer
jurisdiction ofNumber)Identification No.)
incorporation)  
66 Hudson Boulevard East10001-2192
New York, New York (Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code:
(212) 733-2323

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027
PFE/27
New York Stock Exchange
2.875% Notes due 2029
PFE/29
New York Stock Exchange
3.250% Notes due 2032
PFE/32
New York Stock Exchange
3.875% Notes due 2037
PFE/37A
New York Stock Exchange
4.250% Notes due 2045
PFE/45
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐




Item 5.07 Submission of Matters to a Vote of Security Holders
(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 23, 2026.
(b) Shareholders voted on the matters set forth below.
1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 12, 2026 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes:
Nominee
Votes For      
Votes Against
Abstentions
Broker non-vote
Ronald E. Blaylock3,442,653,662102,600,74811,374,500941,392,137
Albert Bourla3,261,211,737272,132,57323,284,563941,392,137
Mortimer J. Buckley3,403,974,675141,036,93211,617,303941,392,137
Susan Desmond-Hellmann3,401,932,807141,056,14713,639,956941,392,137
Joseph J. Echevarria2,929,511,380612,413,50214,702,274941,392,137
Scott Gottlieb3,415,886,776130,394,18510,343,738941,392,137
Dan R. Littman3,383,769,589161,740,87211,118,449941,392,137
Shantanu Narayen3,313,318,763231,613,93211,695,915941,392,137
Suzanne Nora Johnson3,272,936,863273,506,15110,185,896941,392,137
James Quincey3,453,778,74191,549,23611,300,933941,392,137
James C. Smith3,284,035,682261,217,69911,375,529941,392,137
Cyrus Taraporevala3,468,177,42376,665,72111,785,766941,392,137
2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was approved based upon the following votes:
Votes for approval
4,160,827,231
Votes against
321,979,096
Abstentions
15,214,720
Broker non-votes
n/a
3. The proposal to approve the Pfizer Inc. 2019 Stock Plan, as amended April 2026 was approved based upon the following votes:
Votes for approval
3,227,692,578
Votes against
305,428,376
Abstentions
23,507,956
Broker non-votes
941,392,137



4. The proposal to approve, on an advisory basis, the 2026 compensation of the Company's Named Executive Officers was approved based upon the following votes:
Votes for approval
3,099,249,442
Votes against
423,935,881
Abstentions
33,443,287
Broker non-votes
941,392,137
5. The shareholder proposal to Adopt Adopt An Independent Chair Policy was not approved based upon the following votes:
Votes for approval
1,015,206,372
Votes against
2,509,042,021
Abstentions
32,354,566
Broker non-votes
941,392,137










































SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 PFIZER INC.
   
   
Dated: April 27, 2026By:/s/ Margaret M. Madden
 Margaret M. Madden
  Senior Vice President and Corporate Secretary
  Chief Governance Counsel